Cell injection into belly for advanced ovarian cancer with fluid buildup
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new type of therapy where special cells (called SK-NK cells) are injected directly into the belly to treat fluid buildup (ascites) caused by advanced ovarian cancer. It is for patients whose cancer has not responded to at least two prior treatments and who have no other standard options left.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman between 18 and 75 years old.
- You need to have advanced ovarian cancer that has spread, with at least 2 liters of fluid buildup in your belly (called ascites).
- You must have tried at least two standard treatments that didn't work or were not tolerated, and no other standard options are left.
- You should be in generally good health, able to walk and take care of yourself (ECOG 0-2), and expected to live at least 3 more months.
- Your organs (like kidneys, liver, and blood cells) must be working well enough based on recent blood tests.
- You cannot have had other experimental cell treatments before or have certain health conditions like active infections, severe heart problems, or an autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a new drug for ovarian cancer that has spread and caused fluid buildup in the abdomen. It may help control the disease and reduce symptoms.
This early-stage trial tests NK521, a new immunotherapy infusion, for patients with advanced solid tumors (like liver, stomach, or colon cancer) that have spread and caused fluid buildup in the belly. The goal is to see if NK521 can help shrink tumors and improve survival when standard treatments have stopped working.
This early-phase trial tests an experimental drug called GK02 for people with advanced cancer who have fluid buildup in the belly (malignant ascites). The drug is given directly into the belly to try to reduce the fluid and control symptoms.
This trial tests a new injection called CEL001 for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The goal is to see if it is safe and find the right dose.
This trial is testing a new drug, LBL-024, combined with chemotherapy (with or without a targeted therapy called bevacizumab) for ovarian cancer that has stopped responding to standard platinum-based treatment. The goal is to see if this combination can effectively shrink tumors and slow the disease's progression.
This trial tests an experimental natural killer (NK) cell therapy for advanced solid tumors that also cause fluid buildup in the abdomen (malignant ascites). It may help shrink tumors and reduce fluid, but it's very early stage (phase 1/2), so safety and effectiveness are still being studied.
Hear when a new Ascites trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.